The Patent Finder
CT

Curasen Therapeutics, Inc.

First filing 2020
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Nine patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Mar 2040. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2040
Next term end
5
Patent families

When these terms end

Each bar runs from grant to computed term end. 2021 to 2042.
US 11,040,944 Beta Adrenergic Agonist and Methods of Using the Same Mar 26, 2040
US 10,947,196 Beta Adrenergic Agonist and Methods of Using the Same Mar 26, 2040
US 12,448,352 Beta Adrenergic Agonist and Methods of Using the Same Mar 26, 2040
US 12,790,299 Beta Adrenergic Agonist and Methods of Using the Same Sep 23, 2040
US 11,590,107 METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH a1A-AR PARTIAL AGONISTS no later than Dec 3, 2040
US 11,607,395 Methods for Improving Neurological Diseases and Disorders Apr 10, 2041
US 12,558,325 Methods for Improving Neurological Diseases and Disorders Apr 10, 2041
US 12,616,667 Compositions and Methods for Improving Neurological Diseases and Disorders no later than Nov 14, 2042
US 12,723,038 ALPHA1A-ADRENERGIC Receptor Agonists and Methods of Use Dec 18, 2042
202520292033203720412042
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
14 pending applications: term is not computable until grant.Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Fee deadlines

No maintenance fee falls due on this company's record before Nov 17, 2027.

Recent changes

  • 2 of the patents on this record were granted since Aug 20, 2026

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 9 of 9

PatentTitleStatusExpiresConfidence
US 10,947,196Beta Adrenergic Agonist and Methods of Using the Same
In force
 · High confidence
In forceHigh confidence
US 11,040,944Beta Adrenergic Agonist and Methods of Using the Same
In force
 · High confidence
In forceHigh confidence
US 12,448,352Beta Adrenergic Agonist and Methods of Using the Same
In force
 · High confidence
In forceHigh confidence
US 12,790,299Beta Adrenergic Agonist and Methods of Using the Same
In force
 · High confidence
In forceHigh confidence
US 11,590,107METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH a1A-AR PARTIAL AGONISTS
In force
 · Medium confidence
In forceMedium confidence
US 11,607,395Methods for Improving Neurological Diseases and Disorders
In force
 · High confidence
In forceHigh confidence
US 12,558,325Methods for Improving Neurological Diseases and Disorders
In force
 · High confidence
In forceHigh confidence
US 12,616,667Compositions and Methods for Improving Neurological Diseases and Disorders
In force
 · Medium confidence
In forceMedium confidence
US 12,723,038ALPHA1A-ADRENERGIC Receptor Agonists and Methods of Use
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 9: 14 applications pending · 7 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited